Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. (ChromoKey)

November 9, 2026 updated by: Kidney Cancer Research Bureau

An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.

Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.

Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.

These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.

Study Overview

Detailed Description

ChromoKey is a prospective, open-label, multicenter, two-cohort, non-randomized phase 2 study evaluating the efficacy and safety of first-line lenvatinib plus pembrolizumab (Cohort A) and later-line lenvatinib plus everolimus (Cohort B) in patients with metastatic chromophobe renal cell carcinoma (chRCC).

The study enrolls 40 patients across two independent cohorts, with 20 patients in each cohort. Eligible patients are adults with histologically confirmed metastatic chRCC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients from all International Metastatic RCC Database Consortium (IMDC) risk groups are eligible.

Cohort A includes patients who have received no previous systemic therapy for metastatic disease. Patients receive lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks.

Cohort B includes patients whose disease progresses following previous systemic therapy and who have not previously received lenvatinib. Patients receive lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity.

The primary endpoint is the objective response rate in each cohort, defined as the proportion of patients achieving a complete or partial response according to RECIST version 1.1.

Secondary endpoints include progression-free survival, overall survival, duration of response, and safety. Tumor response is evaluated using radiological assessments, and safety is assessed through monitoring of adverse events, clinical examinations, and laboratory investigations.

Each cohort is evaluated independently to characterize the activity and tolerability of the respective combination in its treatment setting. The study does not include randomization or a formal comparison between the two cohorts.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Chelyabinsk, Russia
        • Recruiting
        • Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
        • Contact:
      • Krasnoyarsk, Russia
        • Recruiting
        • V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
        • Contact:
      • Orenburg, Russia
        • Recruiting
        • Orenburg Regional Cancer Center
        • Contact:
      • Saint Petersburg, Russia
        • Recruiting
        • Dr. Berezin Medical Institute
        • Contact:
      • Saint Petersburg, Russia
        • Recruiting
        • SBHI Leningrad regional clinical hospital, Saint-Petersburg
        • Contact:
      • Saratov, Russia
        • Recruiting
        • Saratov Regional Cancer Center
        • Contact:
      • Ufa, Russia
        • Recruiting
        • Republican Clinical Oncology Dispensary
        • Contact:
      • Yekaterinburg, Russia
        • Recruiting
        • Sverdlovskiy Regional Oncological Dispensary
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Histologically confirmed chromophobe renal cell carcinoma.
  • Measurable disease according to RECIST version 1.1.
  • ECOG performance status of 0-3.
  • Cohort A: No prior systemic therapy for metastatic disease.
  • Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
  • Adequate bone marrow, hepatic, and renal function.
  • Signed informed consent.

Exclusion Criteria:

  • Uncontrolled or symptomatic central nervous system metastases or leptomeningeal disease.
  • Uncontrolled hypertension despite appropriate antihypertensive treatment.
  • Clinically significant uncontrolled cardiovascular disease.
  • Active infection requiring systemic treatment.
  • Active clinically significant bleeding or a high risk of severe hemorrhage.
  • Major surgery without adequate postoperative recovery or a serious non-healing wound.
  • Gastrointestinal conditions that significantly impair the absorption of oral study medications.
  • Known severe hypersensitivity to any component of the assigned study treatment.
  • Current pneumonitis or interstitial lung disease.
  • Pregnancy or breastfeeding.
  • Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
  • Cohort A only: Active autoimmune disease requiring systemic immunosuppressive treatment, or a requirement for chronic systemic immunosuppression, excluding physiological corticosteroid replacement.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort A: first-line lenvatinib plus pembrolizumab

lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks

tablets

solution

Experimental: Cohort B: later-line lenvatinib plus everolimus

lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily

tablets

tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate
Time Frame: 12 months

the proportion of patients achieving a complete or partial response according to RECIST version 1.1

12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
progression-free survival
Time Frame: 24 months

the time from treatment initiation to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

24 months
overall survival
Time Frame: 24 months

the time from treatment initiation to death from any cause

24 months
duration of response
Time Frame: 24 months

the time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first

24 months
Grade 3 and higher treatment-emergent adverse events
Time Frame: 24 months

the proportion of patients experiencing at least one treatment-emergent adverse event of grade 3 or higher according to NCI CTCAE version 5.0.

24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2025

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

December 30, 2027

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Study results are disseminated through scientific publications and conference presentations in aggregate form.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe